Poseida Therapeutics Inc expected to post a loss of 66  cents a share - Earnings Preview

Poseida Therapeutics

06/05/2022 12:01

* Poseida Therapeutics Inc  PSTX.OQ   PSTX.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 9
(estimated). 
    * The San Diego California-based  company is expected to
report
revenue of $625 thousand, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Poseida
Therapeutics Inc
is for a loss of 66 cents per share. For the same quarter last
year, the company reported a loss of 62 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $21.5​, above​ its last closing price
of $2.75. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.44       -0.35      0.02      Beat    105.8
 Sep. 30 2021  -0.74       -0.74      -0.68     Beat    8.5
 Jun. 30 2021  -0.63       -0.63      -0.74     Missed  -17.5​
 Mar. 31 2021  -0.64       -0.63      -0.62     Beat    2.4
 ​​Dec.        -0.69       -0.69      -0.58     Beat    15.5
 31 2020                                                
 Sep. 30 2020  -0.55       -0.55      -0.63     Missed  -14.5​
 Jun. 30 2020  -1.48       -1.48      -2.28     Missed  -54.1
 This summary was machine generated May 6 at 11:01 GMT.  All
figures in US dollars  unless otherwise stated